



### Company Overview

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including SY-1425, a first-in-class oral selective RAR $\alpha$  agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia, SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia, and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.

### Syros Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Mar 4 2021, 7:30 AM EST

### Syros to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 4, 2021

Feb 25 2021, 8:01 AM EST

### Stock Overview

Symbol	SYRS
Exchange	Nasdaq
Market Cap	490.31m
Last Price	\$7.96
52-Week Range	\$4.27 - \$15.65

03/04/2021 04:00 PM EST

### Investor Relations

Stern Investor Relations, Inc.  
Hannah Deresiewicz  
[hannahd@sternir.com](mailto:hannahd@sternir.com)

### Management Team

#### Nancy Simonian, M.D.

President and Chief Executive Officer

#### Eric R. Olson, Ph.D.

Chief Scientific Officer

#### Gerald E. Quirk

Chief Legal and Administrative Officer

#### David A. Roth, M.D.

Chief Medical Officer

#### Jeremy P. Springhorn, Ph.D.

Chief Business Officer

#### Joseph J. Ferra

Chief Financial Officer

#### Kristin Stephens

Chief Development Officer

### Syros Pharmaceuticals, Inc.

35 CambridgePark Drive  
4th Floor  
Cambridge, MA 02140

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.